Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial

NCT06646978 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

787

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia (CML)

Interventions

DRUG: Imatinib (STI571)

Sponsor

Poitiers University Hospital